Image credit: shutterstock
GC Biopharma, a South Korean biopharmaceutical company, has successfully obtained final approval from the Indonesian Ministry of Health for the construction of a plasma fractionation plant and technology transfer.
Earlier in January, the company was successfully selected by the Indonesian government as the preferred bidder for the license of plasma fractionation plant construction and technology transfer business. After some detailed consultation and fine-tuning discussions, the company has received an official approval notice for the business.
GC Biopharma is the only company worldwide that has successfully completed the turnkey project of a plasma fractionation plant in an overseas market. Since its first export of a plasma fractionation plant to Thailand, GC Biopharma has been accumulating expertise and know-how in overseas plant construction through successful projects in various countries including China and Canada.
The plant project is the Indonesian government's roadmap to realising a stable and self-sufficient supply of plasma derivatives derived from the plasma of Indonesian people. Currently, the county relies 100 percent on imported plasma derivatives.
GC Biopharma first began producing albumin in the 1970s and since then on, it has been producing various plasma derivatives. Currently, the company supplies 12 products to 32 nations worldwide from its Ochang plant. Established in 2009, the Ochang plant is Asia's largest plasma fractionation plant.
